Why TransMedics Fell 15.7% This Week

Source The Motley Fool

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence.

TransMedics was the target of an activist short-seller late last week, and on Monday of this week, the company responded to the accusations at an industry health conference.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

While the stock initially bounced back a bit after the conference, it continued to fall through the week, as investors still appear to be skittish over the controversy.

Scorpion attacks

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices.

TransMedics has developed a new type of organ transplant technology called the Organ Care System (OCS), which provides oxygen and nutrients to organs during transport. This new technology aims to supplant the current standard of cold storage, which is basically freezing the organ.

Scorpion's report includes a number of allegations. Some of these are that the OCS doesn't work nearly as well as the company lets on, that TransMedics uses thuggish tactics to get hospitals to take on its organs and to push sales, and that the company has antagonized customers by withholding organs if payments haven't come through. Scorpion also pointed to emerging competitive concerns, among other issues.

On Monday, TransMedics gave a full-throated defense of its business in a press release, and also in its presentation at the J. P. Morgan Healthcare Conference. The press release said Scorpion's report had "no merits" and that it "fails to accurately represent TransMedics' business, technology, diverse culture and steadfast focus on delivering exceptional products and services to meet the needs of the global transplant community." The company also said it was engaging a law firm to discuss legal options.

In the first part of his presentation at the conference, CEO Waleed Hassanein suggested that since TransMedics is in the process of disrupting established players in organ transplant, those competitors may be "driving a lot of the dynamics you guys are seeing" regarding the short report.

Who should investors believe?

TransMedics can't seem to catch a break recently, as the company disappointed investors with a growth slowdown in its third-quarter earnings release and fourth-quarter guidance. Its CFO also stepped down back in December. The stock is now down 66% from its all-time highs, reached just this past summer.

If the Scorpion report turns out to have some truth, there is obviously further downside. However, if TransMedics is correct and its technology and business are eventually vindicated, the upside potential is still substantial, according to the company's long-term guidance.

Interested investors may want to take a page out of Peter Lynch's book and "invest in what you know." For instance, if you happen to know a surgeon, other physician, nurse, or administrator who works with organ transplants, questioning them as to whether they've worked with TransMedics' OCS and how they did with the technology could yield insights into this controversial stock. Otherwise, it may be hard to build conviction until more information comes to light.

Should you invest $1,000 in TransMedics Group right now?

Before you buy stock in TransMedics Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $818,587!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of January 13, 2025

JPMorgan Chase is an advertising partner of Motley Fool Money. Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase and TransMedics Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Elon Musk is doing nothing to stop Tesla’s downfallTesla sales are collapsing worldwide, and Musk’s chaotic leadership and focus on political power plays are doing nothing to stop the downfall. The start of 2025 has been troubling, particularly in Europe, where Tesla saw a 45% drop in new registrations in January compared to the same period in 2024, with further declines in February. […]
Author  Cryptopolitan
Mar 24, Mon
Tesla sales are collapsing worldwide, and Musk’s chaotic leadership and focus on political power plays are doing nothing to stop the downfall. The start of 2025 has been troubling, particularly in Europe, where Tesla saw a 45% drop in new registrations in January compared to the same period in 2024, with further declines in February. […]
placeholder
Nvidia stock sinks 4% as Trump’s tariff plans rattle AI tradeNvidia shares fell over 4% early Monday after US President Donald Trump delivered a stern message about trade tariffs. Trump said on Sunday that no country would be given any special treatment regarding tariffs. He also signed new trade policies into effect on April 2, which he calls “Liberation Day.” This frightened investors, who had […]
Author  NewsBTC
Yesterday 01: 15
Nvidia shares fell over 4% early Monday after US President Donald Trump delivered a stern message about trade tariffs. Trump said on Sunday that no country would be given any special treatment regarding tariffs. He also signed new trade policies into effect on April 2, which he calls “Liberation Day.” This frightened investors, who had […]
placeholder
XRP Price Set For ‘Hot’ April With Low Fibonacci Levels And High $5-$8 TargetThe past 24 hours have been challenging for XRP holders. A sharp 5.8% decline in price has brought the asset close to testing critical support around $2, with selling pressure currently dominating XRP’s trading volume. The sentiment is turning bearish, but one analyst is confident in the cryptocurrency’s long-term trajectory, predicting that the altcoin is […]
Author  NewsBTC
Yesterday 01: 54
The past 24 hours have been challenging for XRP holders. A sharp 5.8% decline in price has brought the asset close to testing critical support around $2, with selling pressure currently dominating XRP’s trading volume. The sentiment is turning bearish, but one analyst is confident in the cryptocurrency’s long-term trajectory, predicting that the altcoin is […]
placeholder
PEPE Price Forecast: PEPE could rally to double digits if it breaks above its key resistance levelPepe (PEPE) memecoin approaches its descending trendline, trading around $0.000007 on Tuesday; a breakout indicates a bullish move ahead.
Author  FXStreet
20 hours ago
Pepe (PEPE) memecoin approaches its descending trendline, trading around $0.000007 on Tuesday; a breakout indicates a bullish move ahead.
placeholder
Gold price hits new all-time high ahead of Trump’s reciprocal tariffsGold price (XAU/USD) edges higher again for a second day this week and for the first day of the second quarter of 2025.
Author  FXStreet
15 hours ago
Gold price (XAU/USD) edges higher again for a second day this week and for the first day of the second quarter of 2025.
goTop
quote